Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study.

ABSTRACT:

Background

Biliary tract cancer (BTC) is a dismal disease, even after curative intent surgery. We conducted this prospective, non-randomized phase II study to evaluate the feasibility and efficacy of cisplatin and gemcitabine as adjuvant treatment in patients with resected BTC.

Methods

Patients initially received gemcitabine 1000 mg/m² alone on days 1, 8 and 15 every 28-days for a total of six cycles (single agent cohort), and after protocol amendment a combination therapy with gemcitabine 1000 mg/m² and cisplatin 25 mg/m² on days 1 and 8 was administered every 21 days for a total of eight cycles (combined regimen cohort). Treatment was planned to start within eight weeks after curative intent resection. Adverse events, disease-free survival

SUBMITTER: Siebenhuner AR 

PROVIDER: S-EPMC5765636 | biostudies-literature | 2018 Jan

REPOSITORIES: biostudies-literature